Live Breaking News & Updates on Design therapeutics inc

Stay informed with the latest breaking news from Design therapeutics inc on our comprehensive webpage. Get up-to-the-minute updates on local events, politics, business, entertainment, and more. Our dedicated team of journalists delivers timely and reliable news, ensuring you're always in the know. Discover firsthand accounts, expert analysis, and exclusive interviews, all in one convenient destination. Don't miss a beat — visit our webpage for real-time breaking news in Design therapeutics inc and stay connected to the pulse of your community

Design Therapeutics, Inc. (NASDAQ:DSGN) Director Purchases $66,605.66 in Stock

Design Therapeutics, Inc. (NASDAQ:DSGN – Get Free Report) Director John P. Schmid purchased 17,809 shares of Design Therapeutics stock in a transaction dated Monday, March 25th. The shares were bought at an average price of $3.74 per share, with a total value of $66,605.66. Following the completion of the acquisition, the director now directly owns […]

United-states , Canada , Johnp-schmid , Securities-exchange-commission , Group-plc , Nisa-investment-advisors , Design-therapeutics-inc , Tower-research-capital , Royal-bank , Nasdaq , Design-therapeutics-company-profile

Design Therapeutics, Inc. (NASDAQ:DSGN) Director John P. Schmid Acquires 17,809 Shares

Design Therapeutics, Inc. (NASDAQ:DSGN – Get Free Report) Director John P. Schmid acquired 17,809 shares of the company’s stock in a transaction that occurred on Monday, March 25th. The stock was purchased at an average price of $3.74 per share, for a total transaction of $66,605.66. Following the purchase, the director now owns 26,965 shares […]

United-states , Blackrock , Nova-scotia , Canada , Johnp-schmid , Design-therapeutics-company-profile , Royal-bank , Securities-exchange-commission , Capital-management , Goldman-sachs-group-inc , Blackrock-inc

Insider Buying: Design Therapeutics, Inc. (NASDAQ:DSGN) Director Purchases 9,156 Shares of Stock

Design Therapeutics, Inc. (NASDAQ:DSGN – Get Free Report) Director John P. Schmid bought 9,156 shares of the company’s stock in a transaction on Friday, March 22nd. The stock was purchased at an average cost of $3.62 per share, with a total value of $33,144.72. Following the completion of the transaction, the director now owns 9,156 […]

United-states , Canada , American , America , Johnp-schmid , America-corp , Design-therapeutics-inc , Manufacturers-life-insurance-company , Tower-research-capital , Nasdaq , Royal-bank

John P. Schmid Acquires 9,156 Shares of Design Therapeutics, Inc. (NASDAQ:DSGN) Stock

Design Therapeutics, Inc. (NASDAQ:DSGN – Get Free Report) Director John P. Schmid acquired 9,156 shares of Design Therapeutics stock in a transaction on Friday, March 22nd. The stock was acquired at an average cost of $3.62 per share, for a total transaction of $33,144.72. Following the completion of the purchase, the director now owns 9,156 […]

Canada , United-states , Johnp-schmid , Nasdaq , Design-therapeutics-company-profile , Tower-research-capital , Securities-exchange-commission , Hermes-inc , Group-plc , Royal-bank , Nisa-investment-advisors

Design Therapeutics And 2 Other Stocks Under $5 Insiders Are Buying - FTC Solar (NASDAQ:FTCI), Design Therapeutics (NASDAQ:DSGN)

The Dow Jones index closed lower by over 150 points on Monday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.

Josephk-schachle , Ahmadr-chatila , Ocuphire-pharma , Niravs-jhaveri , Heathera-berger , Johnp-schmid , Ocuphire-pharma-inc , Solar-inc , Design-therapeutics-inc , Dow-jones , Ocuphire-pharma-does , Design-therapeutics

Design Therapeutics (NASDAQ:DSGN) Earns Neutral Rating from Wedbush

Design Therapeutics (NASDAQ:DSGN) Earns Neutral Rating from Wedbush
theenterpriseleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theenterpriseleader.com Daily Mail and Mail on Sunday newspapers.

United-states , Design-therapeutics-inc , Algert-global , Nasdaq , Jump-financial , Barclays-plc , Design-therapeutics , Free-report , Design-therapeutic , Exoduspoint-capital-management , Point-capital-management

Design Therapeutics to Webcast Fourth Quarter and Full Year 2023 Financial Results and ...

CARLSBAD, Calif., March 12, 2024 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a biotechnology company developing treatments for serious degenerative genetic diseases, today announced that the company will host

Nasdaq , Strategic-communications , Design-therapeutics-inc , Nation-world , Egion ,

Design Therapeutics to Webcast Fourth Quarter and Full Year 2023 Financial Results and Comprehensive Portfolio Update

12.03.2024 - CARLSBAD, Calif., March 12, 2024 (GLOBE NEWSWIRE) - Design Therapeutics, Inc. (Nasdaq: DSGN), a biotechnology company developing treatments for serious degenerative genetic diseases, today announced that the company will host a conference call and ...

Nasdaq , Design-therapeutics-inc , Design-therapeutics-chart , Esign-therapeutics-kurs , Esign-therapeutics-aktie ,

Brokerages Set Design Therapeutics, Inc. (NASDAQ:DSGN) Target Price at $5.67

Brokerages Set Design Therapeutics, Inc. (NASDAQ:DSGN) Target Price at $5.67
theenterpriseleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theenterpriseleader.com Daily Mail and Mail on Sunday newspapers.

Montreal , Quebec , Canada , Piper-sandler , Design-therapeutics-inc , Royal-bank , Nasdaq , Design-therapeutics-company-profile , Principal-financial-group-inc , Unisuper-management-pty-ltd , Design-therapeutics , Get-free-report

Design Therapeutics, Inc. (NASDAQ:DSGN) Receives $5.67 Consensus Target Price from Analysts

Design Therapeutics, Inc. (NASDAQ:DSGN – Get Free Report) has received an average recommendation of “Hold” from the seven research firms that are currently covering the company, MarketBeat.com reports. Seven equities research analysts have rated the stock with a hold rating. The average 1-year target price among brokers that have issued ratings on the stock in […]

Canada , Rodneyw-lappe , Piper-sandler , Corton-capital-inc , Group-plc , Design-therapeutics-inc , Tower-research-capital , Nasdaq , Royal-bank , Sg-americas-securities , Design-therapeutics , Get-free-report